Dr. Shirvan Joined Atox Bio in 2010. Before joining Atox Bio she was the co-founder, EVP R&D and director at Aposense Ltd. Dr. Shirvan led the drug development of Aposense technology from its conception, advancing it from discovery stage to pre-clinical and clinical development while overseeing all related regulatory aspects. Dr. Shirvan earned a PhD in molecular biology from The Hebrew University of Jerusalem, and did post-doctoral research for 4 years at NIH studying the annexin family of calcium-binding proteins.
Healthcare